Simcere Pharmaceutical Group Limited
Research Simcere Pharmaceutical Group Limited (2096.HK) on Bullrun: market cap HKD 28.21B, P/E 16.2, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2096.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 28.21B
- P/E16.2
- Dividend yield1.9%
- Financial periodFY2025
- RevenueCNY 7.73B
- Revenue growth16.5%
- Net incomeCNY 1.34B
- Free cash flowCNY 1.15B
- Gross margin81.6%
Valuation Snapshot
latest market cap is HKD 28.21B; P/E is 16.2; dividend yield is 1.9%.
Peer valuation comparison
Latest P/E is 16.21x versus a Healthcare sector median of 21.69x (25.3% below).
Latest dividend yield is 1.89% versus a Healthcare sector median of 2.41% (21.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 7.73B | CNY 1.34B | CNY 1.15B | 81.6% | 0.54 | CNY 3.51B | CNY 1.19B | CNY 9.41B |
| FY2024 | CNY 6.64B | CNY 722.00M | CNY 615.56M | 80.2% | 0.29 | CNY 1.95B | CNY 1.21B | CNY 7.13B |
| FY2023 | CNY 6.61B | CNY 714.76M | -CNY 828.81M | 75.4% | 0.27 | CNY 2.01B | CNY 1.43B | CNY 7.22B |
| FY2022 | CNY 6.32B | CNY 930.87M | CNY 676.09M | 79.0% | 0.36 | CNY 1.66B | CNY 1.51B | CNY 7.13B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 28.21B | 16.2 | 1.9% | 0.21 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.21 HKD, yield 1.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.17 CNY |
| FY2024 | 0.18 CNY |
| FY2023 | 0.18 CNY |
| FY2022 | 0.18 CNY |
| FY2021 | 0.18 CNY |
About Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor;
ETFs that hold Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| VanEck New China ESG UCITS ETF | 1.07% | 0.60% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Simcere Pharmaceutical Group Limited's market cap?
Simcere Pharmaceutical Group Limited's market capitalization is HKD 28.21B.
What is Simcere Pharmaceutical Group Limited's P/E ratio?
Simcere Pharmaceutical Group Limited's price-to-earnings (P/E) ratio is 16.2.
Does Simcere Pharmaceutical Group Limited pay a dividend?
Simcere Pharmaceutical Group Limited has a dividend yield of 1.9%.
What does Simcere Pharmaceutical Group Limited do?
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials.